NCT03548961View on ClinicalTrials.gov

Organ Preservation in Early Rectal Cancer Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 11, 2018

Primary Completion Date

April 23, 2024

Study Completion Date

March 1, 2027

Conditions
Rectal Cancer
Interventions
DRUG

FOLFOX regimen

FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER

NCT03548961 - Organ Preservation in Early Rectal Cancer Patients | Biotech Hunter | Biotech Hunter